Literature DB >> 11584757

A controlled prospective trial of the prophylactic effect of a single dose of ivermectin against Onchocerca volvulus.

M Boussinesq1, J P Chippaux.   

Abstract

A clinical trial was conducted in Cameroon in order to evaluate in humans the possible effect of a single dose of ivermectin (150 micrograms per kg) on the pre-adult stages of Onchocerca volvulus. The incidence of the skin microfilariae was measured in two groups of patients who initially had negative biopsies, and who were subsequently treated, immediately after the seasonal peak of transmission of O. volvulus, either with a combination of ivermectin + ferrous sulphate, or with ferrous sulphate alone. One year after the treatment, i.e. 14 months after the start of the transmission period, the proportion of patients with positive skin biopsies, and their mean microfilarial loads, did not differ significantly between the two groups. Thus a single dose of ivermectin does not seem to have any perceptible prophylactic effect against O. volvulus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11584757     DOI: 10.1051/parasite/2001083255

Source DB:  PubMed          Journal:  Parasite        ISSN: 1252-607X            Impact factor:   3.000


  4 in total

1.  Identifying sub-optimal responses to ivermectin in the treatment of River Blindness.

Authors:  Thomas S Churcher; Sébastien D S Pion; Mike Y Osei-Atweneboana; Roger K Prichard; Kwablah Awadzi; Michel Boussinesq; Richard C Collins; James A Whitworth; María-Gloria Basáñez
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-17       Impact factor: 11.205

Review 2.  Onchocerciasis drug development: from preclinical models to humans.

Authors:  Adela Ngwewondo; Ivan Scandale; Sabine Specht
Journal:  Parasitol Res       Date:  2021-10-13       Impact factor: 2.289

Review 3.  Post-Infectious Autoimmunity in the Central (CNS) and Peripheral (PNS) Nervous Systems: An African Perspective.

Authors:  Alvin Pumelele Ndondo; Brian Eley; Jo Madeleine Wilmshurst; Angelina Kakooza-Mwesige; Maria Pia Giannoccaro; Hugh J Willison; Pedro M Rodríguez Cruz; Jeannine M Heckmann; Kathleen Bateman; Angela Vincent
Journal:  Front Immunol       Date:  2022-03-09       Impact factor: 7.561

4.  Individuals living in an onchocerciasis focus and treated three-monthly with ivermectin develop fewer new onchocercal nodules than individuals treated annually.

Authors:  Jérémy T Campillo; Cédric B Chesnais; Sébastien D S Pion; Jacques Gardon; Joseph Kamgno; Michel Boussinesq
Journal:  Parasit Vectors       Date:  2020-05-15       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.